CAMBRIDGE, Mass. — January 3, 2019 — Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced the promotion of Holly Whittemore, C.P.A., to Chief Financial Officer and Abbas Kazimi to Vice President of Business Development. Additionally, the company announced the appointment of Alan Collis, Ph.D., to lead the Tyrosine Kinase 2 (Tyk2) Program which will be submitting an IND later this year.
“Holly and Abbas have been integral to Nimbus’ successful achievements over the years, and we are excited to welcome them to their new roles,” said Jeb Keiper, M.S., M.B.A., Nimbus’ President and Chief Executive Officer. “We expect the coming year to be a pivotal one for Nimbus as we progress toward our next clinical program, and we welcome Alan’s deep experience and expertise to shepherd Tyk2 to the clinic in partnership with Annie Chen, M.D., our Chief Medical Officer. With these leadership promotions and addition, we’re ensuring we are soundly positioned for continued growth and success.”
Ms. Whittemore brings to the role of Chief Financial Officer more than 20 years of experience in accounting and finance. Since joining Nimbus in 2009 as one of the company’s first hires, Ms. Whittemore has held the roles of Vice President and Senior Vice President of Finance and Operations. Prior to joining Nimbus, she was Director of Finance at Atlas Venture, where she worked with the U.S. and E.U. Operations Groups. Ms. Whittemore started her career at Coopers & Lybrand, where she spent seven years in the audit practice working with companies in the technology, manufacturing, international and not-for-profit sectors. She is a Certified Public Accountant, and she received her B.S. in Commerce from the University of Virginia.
As Vice President of Business Development, Abbas Kazimi will be responsible for corporate development, partnerships and collaborations, and he will also join Nimbus’ leadership team. Mr. Kazimi joined Nimbus in 2014 as Director of Business Development. In that role he drove several of the company’s key transactions, including the licensing agreement with Genentech in 2015, the sale of Nimbus’ clinical NASH program to Gilead in 2016, and the strategic immunology alliance with Celgene announced in 2017. Prior to joining Nimbus, Mr. Kazimi spent a decade in planning and executing strategic transactions for life sciences clients with industry partners and financial investors across the globe, most recently at Extera Partners, LLC. He earned his M.A. from Harvard University and his B.A. from the University of Texas at Austin.
Dr. Collis started with Nimbus in October 2018 and brings extensive experience in preclinical and early development. Dr. Collis most recently led preclinical functions for Forma Therapeutics and held significant leadership roles in drug metabolism and pharmacokinetics (DMPK) and medicinal chemistry in the large pharma settings of Novartis, Aventis, Rhone Poulenc and Pfizer. He earned his Ph.D. and B.Sc. from the University of Manchester Institute of Science and Technology.
About Nimbus Therapeutics
Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts (USA). Nimbus is pioneering the application of highly-advanced computational technologies to the design and development of novel treatments for substantial and underserved human diseases. The company’s focus on metabolic diseases, cancer and immune-inflammatory disorders reflects the mechanistic relationship between these disorders, and Nimbus’ ability to rapidly tackle well validated targets as well as those that have proven intractable to others. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. To learn more, please visit www.nimbustx.com.
Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications